why choose us

First received: August 19, 2022

Clinical Trial: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Crohn's Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease

Brief Summary: Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.Study periods for the intervention-specific appendix (ISA) will be as follows:A 12-week induction periodA maintenance period from Week 12 to Week 52, andA safety follow-up period up to 16 weeks.The study…

Read more